Breaking News Instant updates and real-time market news.

HUM

Humana

$307.50

-2.87 (-0.92%)

, WBA

Walgreens Boots Alliance

$79.82

-2.11 (-2.58%)

08:25
11/21/18
11/21
08:25
11/21/18
08:25

Humana-Walgreens strategic deal makes sense, takeout less likely, says Leerink

Following a media report saying that Humana (HUM) and Walgreens Boots Alliance (WBA) are in talks to take stakes in each other and possibly expand their retail clinic partnership inked on June 19, Leerink analyst Ana Gupte says she believes it makes strategic sense, though she believes an outright takeout is less likely given the multiple differential. As MCOs backward integrate into care delivery, the analyst believes a closer strategic alignment between the two companies can help Humana better compete with the likes of CVS (CVS)-Aetna (AET) and Optum-UnitedHealth (UNH) in the Medicare Advantage market while allowing Walgreens to further stave off e-commerce threats such as Amazon (AMZN), though Humana maintains its strategic investment focus on the home healthcare setting for Seniors.

HUM

Humana

$307.50

-2.87 (-0.92%)

WBA

Walgreens Boots Alliance

$79.82

-2.11 (-2.58%)

AMZN

Amazon.com

$1,495.60

-16.07 (-1.06%)

CVS

CVS Health

$75.52

-3.02 (-3.85%)

AET

Aetna

$204.15

-3.535 (-1.70%)

UNH

UnitedHealth

$261.52

-4.52 (-1.70%)

  • 27

    Nov

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

  • 02

    Dec

  • 04

    Dec

HUM Humana
$307.50

-2.87 (-0.92%)

11/21/18
JEFF
11/21/18
NO CHANGE
JEFF
Jefferies not sure how Humana would benefit from Walgreens stake
The stake talks between Walgreens Boots Alliance (WBA) and Humana (HUM), as reported last night by the Wall Street Journal, follows in the pattern of the Aetna (AET)/CVS Health (CVS) deal, but it is not fully clear how Humana would benefit from an investment in Walgreens, Jefferies analyst Brian Tanquilut tells investors in a research note. For Walgreens, a partnership approach matches the company's strategy and would help address questions about the long-term viability of the retail pharmacy model, adds the analyst. He believes partnering with Humana helps Walgreens drive market share. Further, a deal could also help strengthen Humana's brand and improve its ability to market directly to prospective insurance lives, especially as healthcare increasingly becomes consumer-focused, Tanquilut says.
11/08/18
JEFF
11/08/18
NO CHANGE
Target $410
JEFF
Buy
Humana price target raised to $410 from $388 at Jefferies
Jefferies analyst David Windley raised his price target for Humana to $410 saying he's encouraged by the company's "solid" Q3 results. The analyst keeps a Buy rating on the shares.
11/08/18
FBCO
11/08/18
NO CHANGE
Target $390
FBCO
Outperform
Humana price target raised to $390 from $370 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for Humana to $390 from $370 following quarterly results. The analyst reiterates an Outperform rating on the shares.
11/08/18
OPCO
11/08/18
NO CHANGE
Target $373
OPCO
Outperform
Humana price target raised to $373 from $350 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for Humana to $373 from $350 after the company produced another quarter of "strong" results and provided a bullish outlook into 2019. Given the company is most leveraged to the high-growth Medicare Advantage business, the analyst remains bullish on the stock for long-term investors. He reiterates an Outperform rating on the shares.
WBA Walgreens Boots Alliance
$79.82

-2.11 (-2.58%)

11/19/18
JEFF
11/19/18
NO CHANGE
JEFF
Jefferies uncovers signs of Amazon expanding prescription drug presence
Jefferies analyst Brian Tanquilut says his proprietary checks of Amazon.com's (AMZN) moves in the pharmacy space indicate that the online retailer has finally made moves to expand PillPack. However, the initial expansion phase appears focused on offering pharmacy services to Amazon employees in Washington. In his most recent webscrape, Tanquilut came across a new prescription license in WA, two pending Rx licenses in New Mexico and Indiana, and pharmacy technician and packaging/shipping job postings all linked to PillPack's Phoenix facility. These new developments signal the beginning of Amazon's prescription expansion via PillPack, Tanquilut tells investors in a research note. If Amazon were to rollout a more extensive PillPack offering to its own employee base, Rite Aid (RAD) could be most exposed to potential script transfers with Walgreens Boots Alliance (WBA) the least exposed among the public drugstores, says the analyst. He still believes that the impact of Amazon's pharmacy entry will take a while to materialize for drug stores CVS Health (CVS) and Walgreens.
10/12/18
RHCO
10/12/18
NO CHANGE
Target $75
RHCO
Hold
Walgreens Boots Alliance price target raised to $75 from $66 at SunTrust
SunTrust analyst David MacDonald raised his price target on Walgreens Boots Alliance (WBA) to $75 after its Q4 earnings beat and FY19 guidance yesterday. The analyst says the results were marked by "solid U.S. pharmacy performance" in spite of the ongoing reimbursement and generic headwinds. MacDonald also keeps his Hold rating, adding that while the company's cash flow remains "robust" and the integration of Rite Aid (RAD) is still on track, he is concerned about the challenging environment and ongoing degradation in gross margins.
10/12/18
LOOP
10/12/18
NO CHANGE
Target $82
LOOP
Buy
Walgreens Boots Alliance price target raised to $82 at Loop Capital
Loop Capital analyst Andrew Wolf raised his price target on Walgreens Boots Alliance to $82 from $80 after its Q4 earnings beat and "constructive" outlook for FY19. The analyst notes however that earnings quality was "mixed", with upside coming from lower-than-modeled share count and tax rate along with curtailment of some of the employee benefits. Wolf also keeps his Buy, noting that the management's FY19 guidance was set "conservatively" with some optimism of normalizing gross margins.
AMZN Amazon.com
$1,495.60

-16.07 (-1.06%)

11/21/18
11/21/18
UPGRADE
Target $65

Neutral
Best Buy upgraded to Neutral following quarterly results at Wedbush
As previously reported, Wedbush analyst Michael Pachter upgraded Best Buy (BBY) to Neutral from Underperform, with a $65 price target, saying it has consistently defied his expectations and the company appears to have settled on the right formula for long-term growth. The analyst applauds Best Buy for its many accomplishments, not least of which is achieving the difficult financial targets it has set for itself year after year. While Pachter stills harbor some concerns, including competition from Amazon (AMZN), he thinks Best Buy is poised to deliver on its promises in the coming years.
11/21/18
OPCO
11/21/18
NO CHANGE
OPCO
AWS has long runway for future growth, says Oppenheimer
Oppenheimer analyst Timothy Horan says that Amazon Web Services (AMZN), AWS, continues to move up the stack improving Security, AI/ML, IoT, Database services and bundling in with infrastructure to maintain prices of legacy services. The analyst expects a number of new features and tools for Lambda, Aurora and Greengrass. He also sees Amazon discussing UC&C, gaming and blockchain. AWS kicked off its hybrid offering with its VMware (VMW) partnership and Kubernetes support, but it still lacks the full stack that Microsoft (MSFT) has for hybrid deployments-which are critical for enterprise customers that want to capture the benefits of the cloud while still maintaining on-premise datacenters for sensitive workloads, he contends. Overall, Horan believes demand remains strong, and thinks only about 25% of total enterprise workloads have moved to the cloud, which gives AWS a long runway for future growth.
11/19/18
RBCM
11/19/18
INITIATION
Target $12
RBCM
Outperform
ADT Inc. initiated with an Outperform at RBC Capital
RBC Capital analyst Seth Weber initiated ADT Inc (ADT) with an Outperform rating and a price target of $12. The analyst cites the company's position as a leading provider in the $28B North America monitored security industry serving over 8M customers. Given the 27% short interest, Weber says ADT is a battleground stock, but he also believes that the perceived risk of competition from Amazon (AMZN) is overstated and that the company's big free cash flows outweighs its high leverage.
11/21/18
ARGS
11/21/18
NO CHANGE
Target $205
ARGS
Buy
AvalonBay price target raised to $205 from $196 at Argus
Argus analyst Jacob Kilstein raised his price target on AvalonBay (AVB) to $205 and kept his Buy rating, citing the company's better than expected Q3 earnings along with his diminishing concerns about housing oversupply in New York over the near term. The analyst specifically expects the company to benefit from Amazon.com (AMZN) selection of New York's Long Island City as a location of its new headquarters. Kilstein believes that the 5% decline in AvalonBay stock price since June of 2017 offers a favorable entry and contends that the headwinds of higher interest rates and oversupply in some area have been priced in.
CVS CVS Health
$75.52

-3.02 (-3.85%)

11/13/18
ARGS
11/13/18
NO CHANGE
Target $100
ARGS
Buy
CVS Health price target raised to $100 from $88 at Argus
Argus analyst Chris Graja raised his price target on CVS Health (CVS) to $100 and kept his Buy rating after its Q3 earnings beat, saying he remains "bullish on the management's ability to find innovative and profitable ways to reduce healthcare costs and deliver better care". The analyst also notes that he sees "significant upside for the shares if the company can close acquisition of Aetna (AET) and deliver on its financial targets". To that end, Graja cites the management's confidence expressed on the earnings call that the transaction can be closed prior to Thanksgiving and yield more than the initially estimated $750M in 2-year synergy benefits.
11/09/18
LOOP
11/09/18
NO CHANGE
Target $80
LOOP
Hold
CVS Health price target raised to $80 from $70 at Loop Capital
Loop Capital analyst Andrew Wolf raised his price target on CVS Health shares to $80 from $70, citing improved sales results from CVS's core business units in Q3 and the company's maintenance of 2018 guidance. He also notes that the sector rotation into more defensive stocks has boosted the valuations of most of the other large-cap names in the group. However, Wolf keeps a Hold rating on CVS shares, noting that while its Q3 adjusted EPS of $1.73 topped consensus, it missed his own $1.78 forecast.
AET Aetna
$204.15

-3.535 (-1.70%)

11/07/18
MSCO
11/07/18
NO CHANGE
Target $100
MSCO
Overweight
CVS Health price target raised to $100 from $80 at Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser said he believes the combination of CVS (CVS) and Aetna (AET) has the potential to transform the delivery of care as he introduced pro forma estimates for the combined company. He noted the wide range of consensus estimates, with EPS ranges from $6.63-$8.21 for 2019 and $7.45-$9.05 for 2020, while telling investors that his own pro-forma EPS forecasts are for $7.57 in 2019 and $8.30 in 2020. In setting up a valuation framework for the combined company, Goldwasser raised his price target on CVS shares to $100 from $80 and keeps an Overweight rating on the stock.
11/08/18
LEER
11/08/18
NO CHANGE
Target $95
LEER
Outperform
CVS Health price target raised to $95 from $85 at Leerink
Leerink analyst David Larsen raised his price target for CVS Health (CVS) to $95 from $85 following quarterly results. The analyst is encouraged that the deal with Aetna (AET) appears to be ready to close in the near-term, which he believes will be a positive catalyst for the stock. Larsen also likes how the PBM selling season seems to be progressing well, better than he had expected, and also likes how CVS seems to be re-focusing on the Retail "Streamline" efforts, which will hopefully result in net savings in 2019. The analyst reiterates an Outperform rating on CVS shares.
UNH UnitedHealth
$261.52

-4.52 (-1.70%)

10/31/18
EVER
10/31/18
NO CHANGE
EVER
Outperform
Gilead sales not at risk from UnitedHealth promotions, says Evercore ISI
Evercore ISI analyst Umer Raffat attributes the pullback today in shares of Gilead Sciences (GILD) to concerns over the company's HIV franchise given UnitedHealth's (UNH) promotions of cheaper alternatives. UnitedHealth (UNH) is offering a rewards plan to patients starting with HIV medications to help promote the use of lower priced drugs, Jefferies analyst Michael Yee pointed out earlier today in a research note. Raffat, however, does not see risk to Gilead's sales from the promotions. UnitedHealth's is proposing a switch to two separate tablets, which is not in the HIV guidelines today, says the analyst. He keeps an Outperform rating on Gilead shares, which are down 6% to $68.00 in afternoon trading.
10/31/18
MZHO
10/31/18
NO CHANGE
Target $94
MZHO
Buy
Mizuho says concerns over UnitedHealth program impact on Gilead seem unwarranted
Mizuho analyst Salim Syed blames UnitedHealth's (UNH) introduction of a new a program, called "My ScriptRewards," that will try to convince plan participants to take a cheaper HIV regimen in return for $500 in debit cards for the weakness in shares of Gilead (GILD). However, the analyst views the worries as unwarranted, noting that Cimduo is the "common thread" between all of the regimens that UnitedHealth's program calls out and it is an inferior drug to Gilead's Biktarvy. Biktarvy is the backbone of the number one recommended regimen according to HHS treatment guidelines, noted Syed, who keeps a Buy rating and $94 price target on Gilead shares.
11/14/18
MSCO
11/14/18
NO CHANGE
MSCO
Overweight
UnitedHealth will likely go as OptumHealth goes, says Morgan Stanley
Morgan Stanley analyst Zack Sopcak noted that UnitedHealth aims to achieve $100B in 2025 revenue for OptumHealth, its provider/services business. He estimates that if OptumHealth were to achieve that $100B revenue aspiration in 2025, it would contribute about 42% of revenue and about 40% of profit growth for the total company over the next seven years. Given this, he thinks "as OptumHealth goes, so will likely UnitedHealth." Sopcak, in his preview note ahead of UnitedHealth's analyst day, wrote: "If the 2010s were the decade of OptumRx, we expect the 2020s to be the decade of OptumHealth." He keeps an Overweight rating on UnitedHealth shares ahead of the analyst event on November 27.
11/20/18
CANT
11/20/18
NO CHANGE
Target $49
CANT
Overweight
Tivity Health shares remain attractive, says Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper reiterates an Overweight rating on Tivity Health (TVTY) with a $49 price target saying the shares at current levels remain attractive. With its Q3 results, Tivity provided positive commentary regarding its efforts to increase enrollment, Halper tells investors in a research note. He believes the shares are attractive even with the pending loss of the remaining UnitedHealth (UNH) business.

TODAY'S FREE FLY STORIES

LLY

Eli Lilly

$106.56

-1.8 (-1.66%)

, ADRO

Aduro Biotech

$2.49

-0.14 (-5.32%)

16:23
12/18/18
12/18
16:23
12/18/18
16:23
Hot Stocks
Eli Lilly, Aduro announce research collaboration for immunotherapy development »

Eli Lilly (LLY) and Aduro…

LLY

Eli Lilly

$106.56

-1.8 (-1.66%)

ADRO

Aduro Biotech

$2.49

-0.14 (-5.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

MDU

MDU Resources

$24.80

-0.39 (-1.55%)

16:22
12/18/18
12/18
16:22
12/18/18
16:22
Hot Stocks
MDU Resources reports record November backlog of $1.6B »

MDU Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$143.64

3.33 (2.37%)

, TWTR

Twitter

$33.73

0.31 (0.93%)

16:22
12/18/18
12/18
16:22
12/18/18
16:22
Hot Stocks
Trump claims Facebook, Twitter, Google 'so biased' towards Democrats »

U.S. President Donald…

FB

Facebook

$143.64

3.33 (2.37%)

TWTR

Twitter

$33.73

0.31 (0.93%)

GOOG

Alphabet

$1,028.79

11.19 (1.10%)

GOOGL

Alphabet Class A

$1,043.31

16.77 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

WIN

Windstream

$2.69

0.15 (5.91%)

16:21
12/18/18
12/18
16:21
12/18/18
16:21
Hot Stocks
Windstream sells fiber assets to Arvig in $49.5M cash deal, to sell $11M more »

Windstream announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$6.68

-0.43 (-6.05%)

16:20
12/18/18
12/18
16:20
12/18/18
16:20
Hot Stocks
McDermott signs a lease for new headquarters »

McDermott International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
12/18/18
12/18
16:20
12/18/18
16:20
Options
Closing CBOE SPX and VIX Index summary for December 18th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIG

Signet Jewelers

$31.23

-0.25 (-0.79%)

16:20
12/18/18
12/18
16:20
12/18/18
16:20
Options
Calls lead puts 10:1 in Signet Jewelers with shares at multi-year lows »

Calls lead puts 10:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRCY

Mercury Systems

$48.42

0.29 (0.60%)

16:19
12/18/18
12/18
16:19
12/18/18
16:19
Hot Stocks
Mercury Systems receives $2.9M follow-on order for SAASM devices »

Mercury Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$106.56

-1.8 (-1.66%)

, ADRO

Aduro Biotech

$2.49

-0.14 (-5.32%)

16:18
12/18/18
12/18
16:18
12/18/18
16:18
Hot Stocks
Eli Lilly, Aduro Biotech announce research collaboration, license agreement »

Eli Lilly and Company…

LLY

Eli Lilly

$106.56

-1.8 (-1.66%)

ADRO

Aduro Biotech

$2.49

-0.14 (-5.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

ADSK

Autodesk

$130.56

3.22 (2.53%)

16:18
12/18/18
12/18
16:18
12/18/18
16:18
Initiation
Autodesk initiated  »

Autodesk initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

PTC

PTC

$83.56

1.23 (1.49%)

16:18
12/18/18
12/18
16:18
12/18/18
16:18
Initiation
PTC initiated  »

PTC initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALKS

Alkermes

$31.83

-1.125 (-3.41%)

16:18
12/18/18
12/18
16:18
12/18/18
16:18
Downgrade
Alkermes rating change  »

Alkermes downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 31

    Jan

LNT

Alliant Energy

$43.91

-0.23 (-0.52%)

16:17
12/18/18
12/18
16:17
12/18/18
16:17
Hot Stocks
Alliant Energy to move its comon stock to Nasdaq »

Alliant Energy will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANSS

Ansys

$150.10

3.71 (2.53%)

16:17
12/18/18
12/18
16:17
12/18/18
16:17
Initiation
Ansys initiated  »

Ansys initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
12/18/18
12/18
16:17
12/18/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$18.87

-0.03 (-0.16%)

16:16
12/18/18
12/18
16:16
12/18/18
16:16
Periodicals
Rice brothers want CEO post at EQT, new board members, WSJ reports »

Toby and Derek Rice, two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
12/18/18
12/18
16:16
12/18/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTCH

Match Group

$41.98

0.93 (2.27%)

16:15
12/18/18
12/18
16:15
12/18/18
16:15
Initiation
Match Group initiated  »

Match Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INAP

Internap

$3.99

-0.14 (-3.39%)

16:12
12/18/18
12/18
16:12
12/18/18
16:12
Earnings
Internap narrows FY18 revenue view to $320M-$324M from $320M-$330M »

Consensus $322,32M. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSTI

ShotSpotter

$29.26

-0.02 (-0.07%)

16:12
12/18/18
12/18
16:12
12/18/18
16:12
Initiation
ShotSpotter initiated  »

ShotSpotter initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCS

Steelcase

$14.28

0.11 (0.78%)

16:10
12/18/18
12/18
16:10
12/18/18
16:10
Earnings
Steelcase sees Q4 EPS 24c-28c, consensus 26c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

UPS

UPS

$97.72

0.8 (0.83%)

, FDX

FedEx

$185.74

3.54 (1.94%)

16:09
12/18/18
12/18
16:09
12/18/18
16:09
Hot Stocks
FedEx slides after cutting outlook citing European weakness, UPS follows »

In after-hours trading,…

UPS

UPS

$97.72

0.8 (0.83%)

FDX

FedEx

$185.74

3.54 (1.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

HTGM

HTG Molecular

$2.40

-0.3 (-11.11%)

16:09
12/18/18
12/18
16:09
12/18/18
16:09
Hot Stocks
HTG Molecular establishes French unit to support expanding growth »

HTG Molecular Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INAP

Internap

$3.98

-0.15 (-3.63%)

16:09
12/18/18
12/18
16:09
12/18/18
16:09
Earnings
Internap sees FY19 revenue $325M-$335M, consensus $340.09M »

Sees FY19 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTGM

HTG Molecular

$2.40

-0.3 (-11.11%)

16:08
12/18/18
12/18
16:08
12/18/18
16:08
Hot Stocks
HTG Molecular establishes French unit to support expanding growth »

HTG Molecular Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.